CL2023000998A1 - Formulación farmacéutica para inhalador presurizado de dosis medidas - Google Patents

Formulación farmacéutica para inhalador presurizado de dosis medidas

Info

Publication number
CL2023000998A1
CL2023000998A1 CL2023000998A CL2023000998A CL2023000998A1 CL 2023000998 A1 CL2023000998 A1 CL 2023000998A1 CL 2023000998 A CL2023000998 A CL 2023000998A CL 2023000998 A CL2023000998 A CL 2023000998A CL 2023000998 A1 CL2023000998 A1 CL 2023000998A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
metered dose
dose inhaler
pressurized metered
pharmaceutical composition
Prior art date
Application number
CL2023000998A
Other languages
English (en)
Inventor
Zambelli Enrico
Bonelli Sauro
Copelli Diego
Dagli Alberi Massimiliano
Usberti Francesca
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2023000998A1 publication Critical patent/CL2023000998A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a una composición farmacéutica que comprende un agente de LABA, opcionalmente en combinación con otros ingredientes activos, una mezcla de por lo menos dos ácidos inorgánicos, un propelente y un cosolvente. La invención también proporciona una composición farmacéutica para el tratamiento de enfermedades respiratorias, tales como asma y EPOC.
CL2023000998A 2020-10-09 2023-04-05 Formulación farmacéutica para inhalador presurizado de dosis medidas CL2023000998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20201060 2020-10-09

Publications (1)

Publication Number Publication Date
CL2023000998A1 true CL2023000998A1 (es) 2023-11-24

Family

ID=72826742

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000998A CL2023000998A1 (es) 2020-10-09 2023-04-05 Formulación farmacéutica para inhalador presurizado de dosis medidas

Country Status (13)

Country Link
US (1) US20230277451A1 (es)
EP (1) EP4225267A1 (es)
JP (1) JP2023546025A (es)
KR (1) KR20230084482A (es)
CN (1) CN116419749A (es)
AU (1) AU2021356146A1 (es)
CA (1) CA3193038A1 (es)
CL (1) CL2023000998A1 (es)
CO (1) CO2023004162A2 (es)
IL (1) IL301617A (es)
MX (1) MX2023003754A (es)
PE (1) PE20240629A1 (es)
WO (1) WO2022074183A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227783A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0673240T3 (da) * 1992-12-09 1999-10-11 Boehringer Ingelheim Pharma Stabiliserede medicinske aerosolopløsningsformuleringer
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
KR20070010159A (ko) * 2004-05-13 2007-01-22 키에시 파르마슈티시 엣스. 피. 에이. 화학안정성이 향상된 약제 에어로졸 제제 생성물
PT2515855E (pt) 2009-12-23 2014-06-11 Chiesi Farma Spa Terapêutica de combinação para dpoc
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
AU2014375301B2 (en) 2013-12-30 2020-03-26 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
US20230080276A1 (en) * 2020-02-20 2023-03-16 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation

Also Published As

Publication number Publication date
WO2022074183A1 (en) 2022-04-14
PE20240629A1 (es) 2024-03-26
AU2021356146A1 (en) 2023-05-04
JP2023546025A (ja) 2023-11-01
IL301617A (en) 2023-05-01
CN116419749A (zh) 2023-07-11
MX2023003754A (es) 2023-04-24
US20230277451A1 (en) 2023-09-07
KR20230084482A (ko) 2023-06-13
CO2023004162A2 (es) 2023-04-17
EP4225267A1 (en) 2023-08-16
AU2021356146A9 (en) 2024-06-27
CA3193038A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
AR101593A2 (es) Formulación superfina de formoterol
AR038641A1 (es) Formulacion superfina de formoterol
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
CL2022002235A1 (es) Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
PE20080204A1 (es) Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
BR112015026053A8 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica
ECSP14028814A (es) Nueva forma de dosificación y formulación de abediterol
AR073796A1 (es) Formulaciones de corticosteroides y sus metodos de tratamiento
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
RS54874B1 (sr) Upotreba kompozicije koja obuhvata formoterol i beklometazon dipropionat za tretman egzacerbacije astme
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
BR112015027247A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
CO2022012207A2 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada
PE20240807A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
AR122228A1 (es) Composiciones de spray nasal antiviral y viricida y métodos de tratamiento relacionados
CO2021017397A2 (es) Una composición de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
BR112022010188A2 (pt) Formulação farmacêutica de solução de aerossol, lata de aerossol, inaladores pressurizados de dose calibrada e uso da referida formulação
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero